CD30-positives anaplastisch gro?zelliges T-Zell-Lymphom unter immunsuppressiver Therapie einer Pityriasis rubra pilaris mit Ustekinumab

详细信息    查看全文

• 作者：Dr. D. Humme (1)
  M. Beyer (1)
  H.-J. R?wert-Huber (1)
  W. Sterry (1)
  S. Philipp (1)
  
• 关键词：Immunsuppressive Therapie ; T ; Zell ; Lymphom ; Anaplastisch gro?zelliges Lymphom ; Biologikum ; Neoplasie ; Immunosuppressive therapy ; T ; cell lymphoma ; Anaplastic large cell lymphoma ; Biologic ; Malignancy
• 刊名：Der Hautarzt
• 出版年：2013
• 出版时间：March 2013
• 年：2013
• 卷：64
• 期：3
• 页码：190-194
• 全文大小：615KB
• 参考文献：1. Askling J, Fahrbach K, Nordstrom B et al (2011) Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 20(2):119-30 CrossRef
  2. Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54(3):692-01 CrossRef
  3. Barth D, Harth W, Treudler R, Simon JC (2009) Successful treatment of pityriasis rubra pilaris (type 1) under combination of infliximab and methotrexate. J Dtsch Dermatol Ges 7(12):1071-074
  4. Bongartz T, Warren FC, Mines D et al (2009) Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 68(7):1177-183 CrossRef
  5. Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275-285 CrossRef
  6. Brown SL, Greene MH, Gershon SK et al (2002) Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the food and drug administration. Arthritis Rheum 46(12):3151-158 CrossRef
  7. Gordon KB, Papp KA, Langley RG et al (2011) Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol [Epub ahead of print]
  8. Jung J, Levin EC, Jarrett R et al (2011) Lymphomatoid drug reaction to ustekinumab. Arch Dermatol 147(8):992-93 CrossRef
  9. Koens L, Senff NJ, Vermeer MH et al (2009) Cutaneous gamma/delta T-cell lymphoma during treatment with etanercept for rheumatoid arthritis. Acta Derm Venereol 89(6):653-54 CrossRef
  10. Lafaille P, Bouffard D, Provost N (2009) Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept. Arch Dermatol 145(1):94-5 CrossRef
  11. Mahé E, Descamps V, Grossin M et al (2003) CD30- T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 149(1):170-73 CrossRef
  12. Mariette X, Matucci-Cerinic M, Pavelka K et al (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70(11):1895-904 CrossRef
  13. Müller H, Gattringer C, Zelger B et al (2008) Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report an review of the literature on biologic therapy. J Am Acad Dermatol 59(5 Suppl):S65–S70 CrossRef
  14. Nast A, Boehncke WH, Mrowietz U et al (2011) S3-guidelines for the treatment of psoriasis vulgaris. Update 2011. J Dtsch Dermatol Ges 9(Suppl 2):S1–S104
  15. Papp KA, Dekoven J, Parsons L et al (2012) Biologic therapy in psoriasis: perspectives on associated risks and patient management. J Cutan Med Surg 16(3):153-68
  16. Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED (2011) Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol 23(12):1150-156 CrossRef
  17. Schafer JA, Kjesbo NK, Gleason PP (2010) Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. J Manag Care Pharm 16(6):402-16
  
• 作者单位：Dr. D. Humme (1)
  M. Beyer (1)
  H.-J. R?wert-Huber (1)
  W. Sterry (1)
  S. Philipp (1)
  
  1. Klinik für Dermatologie, Venerologie und Allergologie, Charité -Universit?tsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland
  
• ISSN：1432-1173

文摘

The development of malignancies during therapy with biologics has been discussed controversially. A patient with extensive pityriasis rubra pilaris failed to respond to standard therapeutic approaches. While receiving immunomodulatory therapy, lastly with ustekinumab, the patient developed a CD30+ anaplastic large cell lymphoma.